6541 RESULTS
Sort By:
Pumping Up Progranulin: Scientists Show New Efforts to Get it Done First Hit on Aggregated Tau: Antisense Oligonucleotide Lowers Tangles Tau Chimeras Do Make Fibrils—and a Chaperone Rips Them Apart Macrophages Blamed for Vascular Trouble in ApoE4 Carriers
While memory problems plague some people with lingering COVID symptoms, researchers do not yet understand what is going wrong in their brains.
Data from TRIAD cohort cast activated microglia, egged on by ApoE4, as harbingers of tau pathology and neurodegeneration. Data from BioFinder hint that other microglia restrain these processes.
One study links early menopause to tangles in early AD, another finds a sex difference in the brain's stress response. Could hormones fuel women’s higher risk of dementia?
The public database includes information about the structure, polarity, and stability of both pathogenic and functional amyloid folds.
Scientists devised fresh approaches for curbing tau tangles that might better reach the protein inside cells, or target several pathologies at once.
The D2 dopamine receptor agonist reduced agitation behaviors in Phase 3 trials of dementia due to AD.
Longitudinal and genetic studies reveal that intelligence underlies cognitive reserve.
Three reviews, two perspectives, and four comments discuss recent advances and opportunities for dementia research.
At AD/PD, scientists zeroed in on endolysosomal mechanisms in microglia that may contribute to neurodegenerative disease. Blending omics with cellular studies leads them from genes and function.
A new PET tracer. Plasma glial fibrillary acidic protein. Two new, promising surrogates for astrogliosis are filling in the Alzheimer’s biomarker toolbox. Both reflect Aβ amyloid better than they do tau tangles.
The following summarizes the presentations delivered on Day 2 of the Neuroscience Conference in Orlando...
IPS cells have created excitement among researchers who see them as more available, easier to make, and less ethically conflicted than embryonic stem cells...
The Elecsys-based assay could run on 100,000 fully automated diagnostic machines worldwide.
The anti-amyloid antibody becomes the first Alzheimer’s treatment in 20 years to receive traditional approval from the FDA. Broader Medicare coverage starts now.
No filters selected
